University of California, Los Angeles

Funding Organization

Awards Grant

  • A5361s: Pitavastatin to Reduce Physical Function Impairment and Frailty in HIV (PREPARE)
  • ACTG Protocol Funds
  • AIDS Clinical Trials Group (ACTG)
  • AIDS Clinical Trials Group Laboratory Center (ACTG)
  • AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections [ACTG LOC: PF Chair A5332]
  • AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections [ACTG LOC: TSG-Sci Comm] Sub award# 1560 G YB529
  • Ancillary to ABC PICU to Study MOD in Critically Ill Children
  • Biological Vulnerability to Chlamydia Trachomatis in Adolescents and Young Women: The Complex Intersection of Cervicovaginal Microbiome, Cervical Maturation, and Mucosal Immunity
  • Clinical Study of STI Screening to Prevent Adverse Birth and Newborn Outcomes
  • Does Aggressive Treatment in Early RA Reduce Biomarkers of Cardiovascular Risk?
  • Genomic Classification of the Heart Transplant Endomyocardial Biopsy
  • Il-21 and Immune Mediated Viral Control, IMVC Pilot Project: "Mechanisms of IL-21 Mediated Immunity"
  • International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Group
  • International Maternal, Adolescent and Pediatric Therapeutics Clinical Trials Network (IMPAACT LC)
  • Leadership And Operations Center (LOC), AIDS Clinical Trial Group (ACTG) (UM1AI068636)
  • Leadership And Operations Center (LOC), AIDS Clinical Trials Group (ACT6) [UM1AI068636]-A5332 Committee Chair Support
  • Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG) (UM1A068636-13)
  • Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/
  • Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/
  • Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/ [Specialty Lab Fixed Rate]
  • Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/[PF Spec. Lab]
  • UAB 1356 - A Phase II Randomized Multicenter Placebo-Controlled Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotropic Liver Transplant (OLT) Recipients with Hepatocellular Carcinoma (HCC)
  • UAB 1356: A Phase II Randomized Multicenter Placebo-Controlled Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotopic Liver Transplant (OLT) Recipients with Hepatocellular Carcinoma (HCC)